Analogues of "Mesaton" in Russia: list, description and instructions for use. Meston, an injection solution in which drugs contains Mesoth

Vertal of heart treatments.

Adrenergic and dopaminergic agents. PBX code with 1c A.

Pharmacological properties.

Pharmacodynamics

Phenylephrine - α1-adrenomimetic, slightly affects β-adrenoreceptors of the heart. It is not a catecholamine, since it contains only one hydroxyl group in the aromatic kernel. IN therapeutic doses Without stimulating action on the central nervous system (or with slightly pronounced). Phenylephrine acts mainly on the cardiovascular system. Causes the narrowing of the arteriole and increase arterial pressure (With possible reflex bradycardia). Compared to norepinephrine and epinephrine, it does not increase blood pressure as sharply, but it acts longer, since less exposed to catechol-o-methyltransferase. In the human body cardiac ejection Peripheral resistance increases slightly and significantly increases. After intravenous administration, the action starts immediately and lasts 5-20 minutes. At subcutaneous I. intramuscular administration The effect develops after 10-15 minutes and continues to about 1 or 2 hours, respectively.

Pharmacokinetics

Phenylephrine with parenteral administration quickly enters the body tissue. The volume of distribution after one-time reception is 340 liters. Phenylephrine is metabolized in the liver involving monoaminoxidase to inactive metabolites, excreted primarily with urine. The half-life is about three hours. The degree of binding to plasma proteins is not fully established. There are no data on the peculiarities of pharmacokinetics in special groups of the population.

Indications for use

For the treatment of hypotensive states (induced drugs), including acute vascular failure induced by the reception of drugs or arising during spinal anesthesia, shock states (including traumatic, toxic), as a vasoconstrictor during local anesthesia.

Method of application and dose

The drug is administered intravenously, subcutaneously, intramuscularly.

In acute decrease in blood pressure, the drug is administered, as a rule, intravenously in doses of 0.1-0.3-0.5 ml of 1% solution in 20 ml of a 5% glucose solution, or in the same volumes of isotonic sodium chloride solution. Introduction is carried out slowly, if necessary, the introduction repeat. The interval between repeated intravenous administrations should be at least 15 minutes. With intravenous drip administration 1 ml of 1% mesaton solution in 500 ml of 5% glucose solution or 0.9% sodium chloride solution. The initial rate of administration ranges from 100 μg to 180 μg per minute, in the future the rate of infusion decreases to 30-60 μg per minute. Subcutaneously and intramuscularly adults are injected in doses from 2 to 5 mg, followed by doses from 1 to 10 mg, if necessary.

To local anesthetics (on 10 ml of anesthetic solution) add 0.3-0.5 ml of 1% mesaton solution.

Higher doses for adults: intravenous - one-time 0.005 g, daily 0.025 g; Subcutaneously and intramuscularly - one-time 0.01 g, daily 0.05 g.

The drug does not apply in children. Data on dosing features in patients with impaired liver or kidney function is absent, since the pharmacokinetics in these categories of patients has not studied. Treatment of elderly people should be carried out with caution (see Sections "Precautions", "Side Action").

In persons with impaired liver and kidney kidney correction of the drug dose is not required.

Side effect

Disturbances from the heart: attacks of angina, tachycardia, bradycardia, ventricular arrhythmia (especially when used in high doses).

Disorders from the vessels: blood hemorrhage in the brain, increase or decrease in blood pressure, the pallor of the skin of the face.

Violations from nervous system: headache, dizziness, irritability, feeling of fear, anxiety or psychotic disorders, weakness, tremor, convulsions, confusion.

Disorders from the gastrointestinal tract: nausea, vomiting, dyspeptic phenomena, hypersalization.

Disorders of the respiratory system, organs chest and mediastinum: DISNNEE, EMD END.

Violations from immune system: Hypersensitivity reactions, skin rash, itching. Disturbing from the skin and subcutaneous fabrics: sweating, the pallor of the skin, the feeling of tingling or the "crawling of goosebumps", when the phenylephrine hit the subcutaneous fabrics during the injection, necrosis of the skin is possible.

Disorders of the skeletal muscular and connective tissue: Muscular weakness. Kidney violations and urinary tract: Violation of the kidney function, urine delay.

The risk of phenylephrine toxicity increases with the use of the elderly.

Contraindications

Hypersensitivity koall active and auxiliarycomponentsmedicinal funds; application in patients taking inhibitorsmonoaminoxidase, or within 14 days after their cancellation; arterial hypertension Any severity, hypertrophiccardiomyopathy, fibrillation of ventricles, acute infarction myocardium expressedperipheral circulation includingocclusionionic Vascular diseases (for risk ischemicgangremen or vessel thrombosis); thyredoxicosis, feochromocytoma; Clotted glaucoma; galotane or cyclopropane anesthesia; age up to 18 years; Pregnancy and breastfeeding (see section "Pregnancy and lactation").

Overdose

Overdose symptoms include headache, nausea, vomiting, enhancement of blood pressure and reflex bradycardia, heart rate disorders, such as ventricular extrasystole and short episodes of paroxysmal golden Tachycardia, paranoid psychosis, hallucinations, confusion of consciousness.

Treatment: intravenously introduces α-adrenoblays short action (fantolamine). In the violation of the heart rhythm, β-adrenoblays (propranolol) are introduced.

Precautions

During treatment, it is necessary to constantly monitor blood pressure. Phenylephrine should be prescribed with caution to patients with diseases and symptoms as:

Diabetes; manifestations of hyperthyroidism (see also the section "Contraindications"); chronic heart failure, angina (phenylephrine can provoke patients with ischemic disease Stenokard attack or aggravate the course of the disease); insignificantperipheral circulation disorders; bradycardia; incomplete blockade of the heart; tachycardia arrhythmia (see also the section "Contraindications"); aneurysms; pronounced stenosis of the mouth of the aorta; Metabolic acidosis, hypercupnia, hypoxia.

Phenylephrine can lead to a reduction in cardiac output. Therefore, an increased caution should be observed when prescribing to patients with severe atherosclerosis, in the elderly and in patients with violations of cerebral or coronary blood circulation. In patients with reduced cardiac emission or coronary heart disease, constant monitoring of vital functions is mandatory, dose titration when blood pressure approaches the lower boundary of the target range. In patients with severe heart failure or cardiogenic shock Phenylephrine can strengthen the manifestations of heart failure as a result of induction of vasoconstrictions (increase in post-load). Special attention should be paid to the risk of extravasia, since the phenylephrine hitting the subcutaneous tissues during injection can cause skin necrosis during injection.

During the treatment period, an ECG, IOC, blood circulation in the limbs and the injection site should be monitored.

In patients with arterial hypertension, in the case of a drug collapse, it suffices to maintain systolic pressure at the level below the usual 30-40 mm Hg. Art.

Before starting or during the treatment of shock states, hypovolemia correction, hypoxia, acidosis or hypercapnia is required.

A sharp increase in blood pressure, severe bradycardia or tachycardia, resistant violations of the heart rhythm require discontinuation of treatment.

To prevent repeated decline in blood pressure after the cancellation of the drug, the dose should be reduced gradually, especially after a long-term infusion. Infusion renewed if systolic blood pressure decreases to 70-80 mm Hg. Art.

It should be borne in mind that use during the treatment of vasoconstrictors during childbirth for the correction of arterial hypotension or as additives to local anesthetics against the background of funds stimulating generic activity (Vasopressin, ergotamine, ergometrine, methyl ergometrine), may entail a persistent increase in blood pressure in the postpartum period.

With age, the amount of adrenoreceptors sensitive to phenylephrine is reduced.

Pregnancy and lactation

Adequate and strictly controlled studies on people and animals about the influence of the drug for pregnant women were not conducted. Information about the ability of the drug to act in breast milk absent. The appointment of phenylephrine at the end of pregnancy or during childbirth can lead to the hypoxia of the fetus and the emergence of bradycardia. Based on this, the drug should not be used during pregnancy and lactation, with the exception of cases of extreme need when the estimated benefit for the mother exceeds the potential risk to the fetus. If necessary, the use of the drug during the period breast-feeding Interrupt.

Impact on the ability to manage transport and work with potentially dangerous mechanisms

Research has not been conducted. During treatment, the patient should not control transport, work with potentially hazardous mechanisms and perform work requiring concentration.

Interaction with other medicines

The vesseloring effect of Mesaton is weakened with joint action with an aminezine and other phenothiazine derivatives.

At owl local application With Furazolidon, Meston can cause hypertensive crisis due to the rapid release of norepinephrine.

Meston reduces the hypotensive effect of diuretics and hypotensive drugs.

Mao inhibitors, increasing the press effect of sympathomimetics, can determine the occurrence of headaches, arrhythmias, vomiting, hypertensive crisisTherefore, when taking patients in Inhibitors of the MAO in the preceding 2-3 weeks. Doses of sympathomimetics should be reduced.

Oxytocin, alkaloid derivatives of ardgetis (ergometrine, ergotamine, methyl ergometrine), tricyclic antidepressants, methylphenidate, OC adrenomimetics can enhance the vasopressive effect and arrhythmogenicity of Mesothon.

Doxapram, Bromocriptine, Cabbergoline, Linzolid also increase the risk of vasoconstriction and / or hypertensive crisis. Sharing with heart glycosides or quinidin increases the risk of arrhythmia.

β-adrenoblocators gently make the cardiosulting activity of the drug. The use of drugs against the background of pre-taking reserpine may cause the development of a hypertensive crisis due to the exhaustion of the stocks of catecholamines in adrenergic endings and increase sensitivity to adrenomimetics. Inhalation anesthetics (including chloroform, enfluran, galotan, isoflurane, methoxyfluran) increase the risk of severe atrial and ventricular arrhythmia, since they dramatically increase the sensitivity of myocardium to sympathomimetics.

Meston reduces the antiagonal effect of nitrates, which, in turn, can reduce the press effect of Mesaton and the risk of arterial hypotension (simultaneous use is allowed depending on the achievement of the necessary therapeutic effect).

Thyroid hormones increase (mutually) the effectiveness of the drug and the associated risk of coronary failure (especially with the coronary atherosclerosis).

The use of Mezaton during childbirth for the correction of arterial hypotension against the background of the use of funds stimulating generic activities (Vasopressin, Ergotamine, Ergometrine, methyl ergometrine) can cause a persistent increase in blood pressure in the postpartum period.

Conditions and shelf life

Store at a temperature not higher than 25 ° C in the original packaging. Keep out of the reach of children. Shelf life - 3 years.

Manufacturer

LLC "Pharmaceutical Company" Health ".

Applicant

LLC "Experimental Plant" SnCls ".

Address

Ukraine, 61013, Kharkov, ul. Shevchenko, 22.

(LLC "Pharmaceutical Company" Health ")

Ukraine, 61057, Kharkov, ul. Vorobyeva, 8.

("Experienced Plant" ONTSLS ")

Instructions for medical application drug

Description of pharmacological action

Stimulates postsynaptic alpha adrenoreceptors. It causes a narrowing arteriole, an increase in blood pressure (with possible reflex bradycardia), an increase in OPS. It has a slight stimulating effect on the head and spinal cord. Reduces blood flow - renal, skin, in organs abdominal cavity and limbs. Narrows pulmonary vessels and increases pressure in pulmonary artery. As a vasoconstrictor has an anti-control action: reduces swelling and hyperemia of the nasal mucosa, the severity of exudative manifestations, restores free breathing; Lowering pressure in paranasal cavities and in the middle ear.

Indications for use

Meston is used to increase blood pressure in hypotension and collapse, with hypotonic disease, in preparation and during operational interventions, infectious diseases, intoxication, for vessel spasms with vasomotor ritin, secretory renal anourcing, as well as to expand the pupil with iris, iridocyclitis.

Form release

an injection solution is 10 mg / ml; ampoule 1 ml with a knife of ampumen tutu cardboard 10;

Pharmacodynamics

As a vesseloring agent, Mesaton stimulates A-adrenoreceptors of blood vessels without affecting the B-receptor apparatus of the heart. Causes spasm arterioles and increases blood pressure (reflex bradycardia). The drug causes the expansion of the pupil and lowers intraocular pressure, while not affecting accommodation. It also has a non-surveyed mydritic effect.

Pharmacokinetics

Biotransformed in the liver and gastrointestinal tract (without the participation of catechol-o-methyltransferase). Exammed by the kidneys in the form of metabolites. The action begins immediately after administration and continues for 20 (after a / in administration) - 50 min (with p / k injection) - 1-2 h (after insertion). When local use is subject to system absorption.

Use during pregnancy

Application during pregnancy and during breastfeeding period is possible only if the potential benefit for the mother exceeds possible risk For the fetus and child.

Contraindications for use

Atherosclerosis, hypertonic disease, tendency to spasm of vessels, age up to 15 years, acute pancreatitis and hepatitis.

Side effects

Excitation, headache, irritability, weakness, hypertension, arrhythmia, inhibition of breathing, pain in the heart, oliguria, tremor limbs, paresthesia, ischemia and skin necrosis at the injection site.

Method of application and dose

With collapse, Mesonton is introduced into a vein in a dosage of 0.3 and 0.5 ml (1% solution) in 40 ml of 20 and 40% glucose solution. Intravenously drip to 1 ml of 1% p-ra on glucose (500 ml of 5% glucose solution).
In the muscle and under the skin: from 0.3 to 1 ml of 1% solution, oral - in 0.01-0.025g 2-3 times a day.
To reduce inflammatory manifestations, they are used by lubrication or instillation 0.25-0.5% solutions.
To expand the pupil: 1-2% Mesaton solution is introduced into a conjunctival bag of 2-3 drops.

Overdose

Manifests itself short episodes of ventricular tachycardia and ventricular extrasystoles, sense of gravity in the head and region of the limbs, an increase in blood pressure. Burrying attack: intravenous administration A and B-adrenoblocators.

Interactions with other drugs

Mao inhibitors, tricyclic antidepressants, oxytocin and sprouting alkaloids enhance the vasospasty effect. Furosemid, phenothiazines, fantolamine weaken pressing action on the vessels. When sharing with reserparies, arterial hypertension is possible.

Precautions when receiving

During the period of treatment, an ECG, blood pressure should be monitored, the pressure of the pulmonary artery, the heart rate, blood circulation in the limbs and in the injection site. In arterial hypertension, it is necessary to maintain the garden at the level, by 30-40 mm Hg. below the usual. Before starting or during the treatment of shock states, the correction of hypovolemia, hypoxia, acidosis, hypercapnia is required. A sharp increase in blood pressure, severe bradycardia or tachycardia, resistant violations of the heart rhythm require discontinuation of treatment. To prevent re-reduction of blood pressure after the discharge of the drug, the dose should be reduced gradually, especially after a long infusion. Infusion renewed if the garden decreases to 70-80 mm Hg.

During therapy, potentially hazardous activities are eliminated, requiring the speed of motor and mental reactions.

Under the local application after suction through the mucous membrane, phenylephrine can cause systemic effects. In this regard, the use of phenylephrine in the form of 10% should be avoided eye drops In infants and elderly patients. The use of 2.5% or 10% phenylephrine solution with MAO inhibitors, as well as within 21 days after their cancellation, should be carried out with caution, because The development of system adrenergic effects is possible.

Storage conditions

List B.: In the place protected from light, at a temperature not higher than 25 ° C.

Shelf life

Belonging to ATX classification:

** Drug reference is intended exclusively for informational purposes. For more information, please contact the manufacturer's annotation. Do not self-medicate; Before starting the use of the drug Meston, you should consult a doctor. EUROLAB is not responsible for the consequences caused by the use of information posted on the portal. Any information on the site does not replace the consultation of the doctor and cannot serve as a guarantee positive effect Drug.

Are you interested in the drug Meston? Do you want to know more detailed information or do you need a doctor inspection? Or do you need an inspection? You can make an appointment to the doctor - Clinic Euro.lab always at your service! Top doctors They will consider you, they will advise, will provide the necessary assistance and make a diagnosis. you also can call a doctor. Clinic Euro.lab Opened for you around the clock.

** Attention! The information presented in this reference book is intended for medical professionals and should not be the basis for self-treatment. The description of the drug Meston is given for review and is not intended to appoint treatment without the participation of a doctor. Patients need a specialist consultation!

If you are interested in any other medicines and medicines, their descriptions and instructions for use, information about the composition and form of release, indications for use and side effects, Methods of application, prices and reviews about drugs or you have any other questions and suggestions - write to us, we will definitely try to help you.

It has a vasoconstrictor effect, when introduced into the body, like adrenaline, heals the vessels, enhances heart abbreviations, increases blood pressure, expanding bronchi, slows down peristaltics.

The drug expands the pupil and reduces intraocular pressure.

ATH code: S01F B01. C01C A06. Preparations, stimulating alpha and alpha + beta-adrenoreceptors.

Indications for use

• Increase blood pressure in hypotonic disease, hypotension at shock, collapse, blood loss, intoxication, infectious diseases, etc.
• Supported paroxysmal tachycardia.
• Preparation and conducting operations under spinal anesthesia.
• Like local vasoconstrictor In the ophthalmologic (expansion of the pupil with ophthalmoscopy, conjunctivitis, irites and iridocyclites in order to prevent the occurrence of synechs) and the otorinolaryngological (vasomotor rhinitis, hay fever, etc.) practices.

Terms of application

Meston introduced subcutaneous or intramuscular 0.3-1 ml of 1% solution; intravenously (slow) - 0.1-0.3 ml of 1% solution; Inside - at 0.01-0.025, with a long-term appointment, 1-2 ml of 1% solution of the drug in 250-500 ml of a 5% solution of glucose is administered intravenously drip.

The highest doses of the drug subcutaneously and intramuscularly: one-time - 0.01 g (1 ml of 1% solution), daily - 0.05 g (5 ml of 1% solution).

With collapse that arose as a result of myocardial infarction, intravenously A 0.3-1 ml of 1% mesaton solution in 20 ml of a 40% glucose solution is administered slowly under the control of blood pressure.

The highest dose of Mesaton intravenously: one-time - 0.005 g (0.5 ml of 1% solution), daily - 0.025 g (2.5 ml of 1% solution).

Inside Meston is prescribed in tablets of 0.01-0.025 g 2-3 times a day.

The highest dose of Mesaton inside: one-time - 0.03 g, daily - 0.15 g.

Most For lubrication and irrigation of mucous membranes, 0.25-0.5% solutions of the drug are used.

1% Mesaton solution is added instead of adrenaline to solutions of local anesthetics for the narrowing of the vessels at the rate of 0.3-0.5 ml of mesaton solution for every 10 ml of anesthetic solution.

In ophthalmology and otorinolaryngology, 0.25-0.5% solutions for lubricants and instillations are used for the narrowing of vessels, with glaucoma - 10% solution in drops.

Sideflines

Headache, nausea (with an increase in blood pressure).

Contraindications

Pronounced atherosclerosis, myocarditis, hypertensive disease (with the exception of collapse). Special care is needed in hyperthyroidism, tendency to vascular spasms, as well as in individuals of the elderly.

Composition and form of release

Release:

Recipe on Mesoth

Rp.:	Mesatoni.	0,01
	D. T. d. N 10 in Tabul.
	S.

• Tablets of 0.01 g (10 mg), 10 tablets per pack.
• 1% solution for injection in 1 ml glass ampoules, in cardboard packs of 10 and 100 ampoules. 1 ml of solution contains: phenylephrine of hydrochloride - 10 mg, excipients: glycerin, water for injection.
• 2.5% solution (eye drops) in 5 ml bottles. 1 ml of solution contains: phenylephrine of hydrochloride - 25 mg, auxiliary substances: decamexin, polyethylene oxide 400, trilone b, purified water.

Shelf life and storage conditions

Store in a dry, cool, light-protected place. Recommended by recipe.

Mesothon's shelf life: Tablets and injection mortars - 3 years, eye drops - 2 years.

Properties

(Mesatonum) - 1- (M-hydroxyphenyl) -2-methylaminoethanol hydrochloride (phenylefrin hydrochloride) - white crystalline powder without odor, easily soluble in water, ethyl alcohol, weak alkalis and acid solutions.

Meston is a adrenomimetic (by mechanism pharmacological action Meston belongs to the group of sympathomimetic amines), actively stimulates alpha-adrenoreceptors, on the beta-receptors of the heart has a weak effect.

The adrenaline Meston differs with a smaller force of pressing action, which can be compensated by an appropriate increase in its dose. The advantage of Mesaton, compared with adrenaline, is a large duration of the effect and the possibility of using the drug not only parenterally, but also inward.

Mesonton racks during sterilization.

Analogs

Almephrine. Visadron. Derizen. Isofrin. Metasimpatol. M-sympathol. Neo-cinephrine. Neofrine. Sympathol. Phenylephrine (Phenylephrine). Phenylefrin hydrochloride. Phenyl Ephritis.

Instructions for use:

Mesafon is a drug with vasoconstrictor and alpha adrenomimetic effect.

Release form and composition

Meston is produced in the form of a solution for injection: transparent, colorless (1 ml in ampoules, in a pack of cardboard 10 ampoules complete with a ceramic cutting disc or ampumen scarifier).

The active ingredient: phenylephrine hydrochloride, in 1 ml - 10 mg.

Auxiliary components: Injection water and glycerin.

Indications for use

• Vascular failure (including due to the overdose of vasodilators);
• Arterial hypotension;
• Allergic and vasomotor rhinitis;
• Shock conditions, including toxic and traumatic shock.

In addition, Meston is used when conducting local anesthesia as a vasoconstrictor agent.

Contraindications

Absolute:

• Hypertrophic obstructive cardiomyopathy;
• Ventricular fibrillation;
• Feochromocytoma;
• Increased sensitivity to the drug.

Relative (should be observed special caution In connection with the risk of developing complications):

• Arterial hypertension, hypertension in a small circle of circulation, atrial fibrillation, ventricular arrhythmia, acute myocardial infarction, heavy stenosis of the aorta mouth, closed-coronal glaucoma, hypoxia, hypovolemia, hypercapnia, tachyarhythmia, metabolic acidosis;
• Occlusive vascular diseases (including a history): Burger's disease (burchitating thrombangiit), atherosclerosis, Reina disease, arterial thromboembolism, the tendency of vessels to spasms (including frostbite), porphyry, diabetes, glucose-6-phosphate dehydrogenase, thyrotoxicosis, diabetic endarterite;
• Simultaneous use of monoaminoxidase inhibitors (MAO);
• Functional disorders of the kidneys;
• Common fluorotan anesthesia;
• Age up to 18 years;
• Elderly age.

Pregnant and nursing breasts, Meston can be appointed only by strict indications, after assessing the benefit ratio and possible risks.

Method of application and dosage

Mesaton solution is administered intravenously (inkjet or drip), intramuscularly or subcutaneously.

The collapse is administered intravenously slowly in a dose of 0.1-0.3-0.5 ml, preliminarily explores 20 ml of 0.9% solution of chloride sodium or 5% dextrose solution. If necessary, introduce another dose.

Drippingally intravenously is administered in a dose of 1 ml, pre-emerging 250-500 ml of a 5% solution of dextrose.

Intramuscularly or subcutaneously Mesoth prescribed an adult in a dose of 0.3-1 ml 2-3 times a day, children over 15 years old with arterial hypotension during spinal anesthesia - In a dose of 0.5-1 mg per kilogram of body weight.

To reduce inflammatory phenomena and narrowing the vessels of the mucous membranes, the drug (at a concentration - 0.125, 0.25, 0.5, 1%) is used for lubricants or injections.

When conducting local anesthesia for every 10 ml, anesthetic solution is added to 0.3-0.5 ml of 1% mesaton solution.

Maximum allowable doses for adults:

• Intravenously: one-time - 5 mg, daily - 25 mg;
• Intramuscularly and subcutaneously: one-time - 10 mg, daily one - 50 mg.

Side effects

• Cardiovascular system: an increase in blood pressure, rapid heartbeat, arrhythmia, ventricular fibrillation, cardialia, bradycardia;
• Central nervous system: insomnia, feeling of fear, anxiety, dizziness, weakness, paresthesia, tremor, convulsions, headache, hemorrhage into the brain;
• Others: Ischemia of the skin at the injection site, the pallor of the skin of the face; In isolated cases - allergic reactions, the formation of a stamp and necrosis (with subcutaneous injections and in the event of a solution in tissue).

special instructions

During treatment, it is necessary to control the indicators of electrocardiogram, blood pressure, blood circulation at the injection site and limbs, minute volume of blood.

Before starting or during the treatment of shock conditions, hypoxia correction, hypovolemia, hypercapinia and acidosis is required.

In the case of a drug collapse in patients with arterial hypertension, it suffices to maintain systolic blood pressure at the level below the usual 30-40 mm Hg.

Resistant rhythm violations, pronounced tachycardia or bradycardia, a sharp increase in blood pressure requires the abolition of Mesothon.

In order to prevent a re-reduction of blood pressure after canceling the drug, the dose is recommended to reduce gradually, especially after a long infusion. However, if systolic blood pressure decreases to a level of 70-80 mm Hg, infusion is renewed.

It should be borne in mind that vasoconstrictors used in addition to local anesthetics simultaneously with funds stimulating generic activities (ergotamine, vasopressin, methyl ergometrine, ergometrine), or intended for the correction of arterial hypotension during childbirth, may result in a persistent increase in blood pressure in the postpartum period .

With age, the amount of adrenoreceptors sensitive to phenylefrine is reduced. Mao inhibitors, increasing the press effect of sympathomimetics, can contribute to the appearance of vomiting, the development of arrhythmias, headaches, hypertensive crisis. For this reason, patients who in previous 2-3 weeks have taken Mao inhibitors, doses of sympathomimetics should be reduced.

During the treatment period, Meson must refrain from the activities of activities requiring the speed of mental and motor reactions, including from driving vehicles.

Medicinal interaction

Possible reactions of interaction in the case of simultaneous use of Mesaton and other drugs:

• Antihypertensive preparations, diuretics: reduction of their hypotensive effect;
• Monoaminoxidase inhibitors (prolobazin, fuzolidone, selegilin), tricyclic antidepressants, arcaloids, adrenostimulants, methylphenidate, oxytocin: enhancement of pressing action and phenylephrine arrhythmogenicity;
• Inhalation anesthetics (galotan, enfluraura, methoxyphluran, isofluran, chloroform): an increase in the risk of developing severe ventricular and atrial arrhythmias;
• Nitrates: Reducing their anti-inanal effect, decrease in the pressing effect of phenylephrine, risk of arterial hypotension;
• Thyroid hormones: synergism of the effects of drugs and strengthening the risk-related risk of coronary insufficiency, especially in patients with coronary atherosclerosis;
• Alpha adrenoblocators, phenothiazines: reduction of hypertensive effect;
• Methyl ergometrine, doxapram, ergotamine, oxytocin, ergometrine: enhancing the severity of vasoconstrictor action;
• Beta-adrenoblocators: reduction of cardiac activity; When applying the reserpine - the risk of arterial hypertension.

Analogs

Analogues of Mesaton are: I am 2.5% I amorgeon, Nazol Kids Spray.

Terms and conditions of storage

Store at temperatures up to 25ºC. Do not expose light. Take care of children.

Shelf life - 3 years.

Registration number

Trade name of the drug: Mesoth

International UnPatented Name:

Phenylephrin

Dosage form:

injection

Structure:

1 ml of solution contains:
active substance phenylephrine hydrochloride -10 mg;
excipients: Glycerin, water for injection.

Description: Transparent colorless liquid.

Pharmacotherapeutic Group:

Alpha adrenomimetic

ATX code C01S06.

Pharmacological properties
Pharmacodynamics
Synthetic alpha 1-adrenostimulator, little affecting the beta adrenoblasts of the heart; It is not a catecholamine (contains only one hydroxyl group in the aromatic kernel). It causes a narrowing of arterioles and an increase in blood pressure (AD) with possible reflex bradycardia. Compared to norepinefrin and epinephrine, the increase in blood pressure is less sharp, but acts more than a long time (little is subject to catechol-o-methyltransferase), it does not cause an increase in the minute volume of blood. The action begins immediately after administration and continues for 20 minutes (after intravenous administration), 50 min (at subcutaneous administration), 1-2 hours (after intramuscular injection).

Pharmacokinetics.
Metabolized in the liver and gastrointestinal tract (without the participation of catechol-o-methyltransferase). Exammed by the kidneys in the form of metabolites.

Indications for use
Collapse, arterial hypotension (associated with a decrease in vascular tone), in preparation for operational intervention and during operations, vasomotor and hanna ritin, intoxication, as a vasoconstrictor with local anesthesia

Contraindications
Increased sensitivity to the drug, hypertrophic obstructive cardiomyopathy (including asymmetric partition hypertrophy), feochromocytoma, tachiaritium, atrial fibrillation, and / or ventricular, metabolic acidosis, hypercaping, hypoxia, arterial hypertension, hypertension in a small circulation circle, hypovolemia, heavy stenosis The mouths of the aorta, acute myocardial infarction, porphyria. Congenital deficiency of glucose-6-phosphate dehydrogenase, a tendency to spasms of vessels, pregnancy, lactation period, age up to 18 years old (efficiency and safety are not established).

Carefully: Ranzametal angina, occlusive diseases of the vascular vessels, including arterial thromboembolism, atherosclerosis, burchitis (burgher disease), frostbite, diabetic endarterite, Reino disease, thyrotoxicosis, elderly age, diabetes, with general anesthesia (fluorotan), renal impairment.

Method of application and dose
Meston is introduced intravenously, subcutaneously, intramuscularly, intranasally. As a collapse, the drug is administered, as a rule, intravenously in doses of 0.1-0.3-0.5 ml of 1% solution, diluting 20 ml of 5% - 20% decrees of dextrose (glucose) or 0.9% sodium solution chloride. Introduction is carried out slowly, if necessary, the introduction repeat. With a drip method, 1 ml of 1% mesaton solution in 250-500 ml of a 5% declaration solution (glucose) is introduced. Subcutaneously and intramuscularly adults are injected in doses of 0.3-1 ml of 1% solution.

In order to narrow the vessels of the mucous membranes of the nasal cavity and reduce the expression of inflammation, 0.25-0.5% solutions or mucous membranes are lubricated with these solutions. To local anesthetics (on 10 ml of anesthetic solution) add 0.3-0.5 ml of 1% mesaton solution.

Higher doses for adults: intravenous - one-time 0.005 g, daily - 0.025 g; subcutaneously and intramuscularly - one-time 0.01 g, daily - 0.05 g.

Side effect
From side of cardio-vascular system: Increased blood pressure, heartbeat, heart ventricle fibrillation, arrhythmia, bradycardia, cardialia.

From the gastrointestinal tract: dyspeptic phenomena;

From the central nervous system: dizziness, feeling of fear, insomnia, anxiety, weakness, headache, tremor, paresthesia, convulsions, hemorrhage into the brain;

Others: The pallor of the skin of the face, the skin ischemia at the injection site, in isolated cases, the necrosis and the formation of the structure are possible when entering the tissue or at subcutaneous injections, allergic reactions.

Overdose
Symptoms: ventricular extrasystole, short ventricular tachycardia paroxysms, sensation of gravity in the head and limbs, a significant increase in hell.

Treatment: intravenous administration of alpha-adrenobloclars (fantolamine) and beta-adrenoblastors (with heart rate disorders).

Interaction with other medicines
Phenothiazines, alpha-adrenoblocators (fantolamine), furosemide and other diuretics reduce the hypertensive effect.

Monoaminoxidase inhibitors, oxytocin, sprouting alkaloids, tricyclic antidepressants, furazolidine, prokarbazin, selegilin, adrenostimulants enhance the press effect, and the last and arrhythmogenicity.

Beta-adrenobloclars reduce the cardiming activity, against the background of the reserpine arterial hypertension (due to the depletion of catecholamines in adrenergic endings, sensitivity to adrenomimetics increases).

special instructions
During the treatment period should be monitored eCG, Ad, minute volume of blood, blood circulation in the limbs and at the injection site.

Before starting or during therapy, the correction of hypovolemia, hypoxia, acidosis, hypercapnia is required.

A sharp increase in blood pressure, severe bradycardia or tachycardia, resistant violations of the heart rhythm require discontinuation of treatment. To prevent re-reduction of blood pressure after the discharge of the drug, the dose should be reduced gradually, especially after a long infusion. Infusion renewed if systolic blood pressure decreases to 70-80 mm Hg. Art.

During therapy should not be engaged hazardous species Activities requiring the speed of motor and mental reactions (including driving a car).

Form release
The injection solution is 10 mg / ml.

1 ml in ampoules embedded in 10 pieces along with the application instructions and scarifier ampumen in a pack of cardboard.

Storage conditions
List B. In the place protected from light and inaccessible to children, at a temperature not higher than 25 ° C.

Shelf life
3 years.

Do not apply the drug after the expiration date indicated on the package!

Conditions of vacation from pharmacies
On prescription.

Enterprise-producer
LLC "Experimental Plant" SnCls ". Address: Ukraine, 61057, Kharkov, ul. Vorobyva, 8.